clinicaltrials.gov dihexa Lexeo Therapeutics shared an update on LX2006, an investigational gene therapy for Friedreich's Ataxia cardiomyopathy. The therapy is currently being studied in an ongoing Phase 1/2 trial, with data helping to inform Variant:200µg scalp-care Contact Us - Living

clinicaltrials.gov dihexa Lexeo Therapeutics shared an update on LX2006, an investigational gene therapy for Friedreich's Ataxia cardiomyopathy. The therapy is currently being studied in an ongoing Phase 1/2 trial, with data helping to inform Variant:200µg scalp-care Contact Us - Living

Contact Us - Living Well Dallas

Hydration & protein mitigate side effects

scalp-care

Variant:200µg

Further randomized trials are needed to define optimal dosing, long‑term safety, and its role among sleep‑optimizing peptides such as CJC‑1295, Ipamorelin, and Epitalon Key sleep‑optimizing peptides highlighted in the article are CJC‑1295, Ipamorelin, Delta Sleep‑Inducing Peptide (DSIP), and Sermorelin